Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 1Q 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after entering the ALG.APV-527 Phase 1 trial with progressive disease and transitioning to higher dose with potential for greater clinical benefit, experienced no new adverse events since the transition to the higher dose level APVO436 Phase 1b/2 dose optimization trial initiation of ...

Core Viewpoint - Aptevo Therapeutics has experienced a significant stock decline of 79.0% following a secondary offering of 3.4 million shares at $1.35 per share, raising $4.6 million in gross proceeds, which is intended to support clinical development and general corporate purposes [1][2][3] Company Overview - Aptevo Therapeutics is a clinical-stage pharmaceutical company focused on developing novel therapies for cancer indications [1] - The company has two candidates in clinical development: APVO436 and ALG.APV527, targeting different oncology indications [2] Stock Performance - Following the announcement of the secondary stock offering, Aptevo's shares plummeted, with a year-to-date decline of 90.2%, compared to an 8.9% decline in the industry [2] - The stock closed at $2.40 on April 10, prior to the announcement, making the offering price a discount that did not favor investors [2] Financial Position - The secondary stock offering aims to strengthen Aptevo's financial position, as the company's preliminary cash balance was reported at $16.9 million at the end of December 2023, which is expected to deplete soon [3] - The proceeds from the offering will be used to fund current business plans and extend the cash runway [3] Clinical Development Plans - Aptevo is evaluating ALG.APV-527 in an early-stage study for multiple solid tumor types and plans to start a phase Ib/II study for APVO436 targeting acute myeloid leukemia (AML) by the end of June 2024 [3]

Aptevo Therapeutics (NASDAQ:APVO) stock is falling on Thursday after the clinical-stage biotechnology company priced a public offering for its shares.That public offering has Aptevo Therapeutics selling 3.4 million shares of APVO stock at a price of $1.35 each. The shares also come with warrants to purchase another 6.8 million shares of the company’s stock.Aptevo Therapeutics notes that the exercise price for the warrants in this offer is also $1.35 per share. The warrants are exercisable immediately and ex ...

As filed with the Securities and Exchange Commission on April 9, 2024. Registration No. 333-278103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 81-1567056 (I.R.S. Employer Identification N ...

As filed with the Securities and Exchange Commission on March 29, 2024. Registration No. 333-278103 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTEVO THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Delaware 2834 81-1567056 (I.R.S. Employer Identification Number) 2401 4th Avenue, Sui ...

As filed with the Securities and Exchange Commission on March 20, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER (Primary Standard Industrial Delaware 2834 81-1567056 (I.R.S. Employer Identification Number) 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 (206) 838-0500 (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices) Marvin L. White THE SECURI ...

Exhibit 99.1 APTEVO THERAPEUTICS REPORTS 2023 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE Announces 1H24 Plan for Development of Lead Candidate APVO436 for the Treatment of Frontline Acute Myeloid Leukemia, Interim Results Expected Late 2H24 ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues Enrollment, Interim Results Expected 1H24 SEATTLE, WA – March 5, 2024 – Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company focused on developing novel immune ...

th | --- | --- | --- | |------------------------------------------------------|------------------|-----------------------------------------------------------------------| | Title of Each Class | Trading Symbol | Name of Exchange on Which Registered | | Common Stock, $0.001 par value per share | APVO | The Nasdaq Stock Market LLC (The Nasdaq Capital Market) | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SEC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | |-----------------------------------------------------------------------------|-------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37746 | --- | --- | --- | |------------------------------------------------------------------------------------------------------- ...